Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

thecryptobasic2026-09-25 14:20:49

Favorite

Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

Moderna Inc. (NASDAQ: MRNA) shares set a fresh 52-week high Friday before giving back the intraday advance, while Bernstein SocGen Group reiterated its Market Perform rating and $45 price target and called intismeran the clearest validation yet of Moderna’s broader mRNA therapeutics platform.

Visit Website

Disclaimer: This article is copyrighted by the original author and does not represent MyToken’s views and positions. If you have any questions regarding content or copyright, please contact us.(www.mytokencap.com)contact

About MyToken:https://www.mytokencap.com/aboutusArticle Link:https://www.mytokencap.com/news/597901.html

More exciting content is available on
X(https://x.com/MyTokencap)or join the community to learn more:MyToken-English Telegram Group
（https://t.me/mytokenGroup）

Previous:AI Agent 的兴起加剧了 AI 能力与社会资源的错配

Next:分析师顾景辞：9.25比特币/以太坊操作策略附行情分析

Cardano DEX Volume Rises 148% in a Week

Cardano’s decentralized finance (DeFi) activity has picked up recently, with decentralized exchanges...

thecryptobasic2026-09-25 16:46:39

XRP Finally Completes Retest of 7-Year-Old Symmetrical Triangle Breakout

XRP has finally completed a retest of the symmetrical triangle breakout that occurred during the Nov...

thecryptobasic2026-09-25 16:04:28

Six-Year Support Pattern Projects Long-Term XRP Price Target

XRP’s six-year support structure and historical cycle pattern map a potential third retest before a ...

thecryptobasic2026-09-25 15:38:12